At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 38 enrolled
Drug / intervention
QVA149 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, 4-week Crossover (Total Duration 12 Weeks), Placebo-controlled, Double-blind Study to Determine the Impact of QVA149 (Indacaterol/Glycopyrronium) 85/43 µg on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 4 clinical trial evaluating QVA149 and QVA149 Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 38 participants across 5 sites in 3 countries.
Detailed Summary
The purpose of this study was to determine whether a fixed dose combination of indacaterol and glycopyrronium (QVA149) has an impact on night-time blood oxygen levels in Chronic Obstructive Pulmonary Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesDenmark, Norway, Sweden
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartNov 2014
Primary CompletionJun 2016
TodayJul 2026
First PostedSep 8, 2014
Enrollment StartNov 30, 2014
Primary CompletionJun 26, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.8 years ago
Interventions
QVA149drug
Delivered once daily via single-dose dry powder inhaler
QVA149 Placebodrug
Placebo delivered once daily via single-dose dry powder inhaler